Highest tertile of REM latency associated with higher A\u03b2 burden, elevated p-tau181, reduced BDNF levels<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Jan. 27, 2025 (HealthDay News) — Prolonged rapid eye movement (REM) latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias (AD\/ADRD), according to a study published online Jan. 27 in Alzheimer’s & Dementia<\/em>.<\/p>\n JIangli Jin, from the China-Japan Friendship Hospital in Beijing, and colleagues enrolled 128 adults (64 with Alzheimer disease, 41 with mild cognitive impairment, and 23 with normal cognition) to examine the relationship between sleep architecture and AD\/ADRD. Participants underwent polysomnography, amyloid \u03b2 (A\u03b2) positron emission tomography, and plasma biomarker analysis, including phosphorylated tau at threonine 181 (p\u2010tau181), neurofilament light, and brain\u2010derived neurotrophic factor (BDNF).<\/p>\n The researchers found that the highest versus the lowest tertile of REM latency was associated with higher A\u03b2 burden, elevated p-tau181, and reduced BDNF levels (\u03b2 = 0.08, 0.19, and \u22120.47, respectively) after adjustment for demographics, apolipoprotein E \u03b54 status, cognition, and comorbidities.<\/p>\n “Prolonged REM latency was associated with key AD\/ADRD pathophysiology, including elevated A\u03b2 deposition and plasma p-tau181 and lower BDNF levels,” the authors write. “Given that these pathological changes typically precede clinical symptoms by a decade or more, our findings may provide novel insights regarding the involvement of REM sleep in the early detection and intervention of AD\/ADRD.”<\/p>\n One author disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n